Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
In the background: Visiting Notable Film Areas All over the Planet - 2DEA seizes 1.7 million counterfeit fentanyl pills in Colorado storage unit
- 3What to know about MIT professor Nuno Loureiro and the investigation into his shooting
- 4Tourist trade in Greece and Cyprus suffering from Iran war effects
- 5Bayer sues COVID vaccine makers over mRNA technology
- Dr. Vinay Prasad's memo raises concerns about COVID-19 vaccines and pediatric mortality
- Solid Propensities: Little Changes for a Superior Life
- Avoid Slam: Exploring the Pickup Truck Transformation
- Charli xcx teases new film ‘The Moment’: What to know about the A24 movie
- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Reconnecting with an old friend is a story of distance, loss and rediscovery
- Vietnam rethinks its flood strategy as climate change drives storms and devastation
- 'Stranger Things' made him a heartthrob. He left Hollywood anyway.
- A hunger for new experiences Narratives: Motivating Travel and Experience
